Conditions: Carcinoid Tumors
Keywords: SOM230 Sandostatin Carcinoid syndrome
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
Study evaluating SOM230 in patients with metastatic carcinoid tumors

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Pasireotide (SOM230)
Intervention descriptions: intervention 1: Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.

Protocol document: